Lilly’s Thanksgiving Turkey: Lessons From Another Failed Alzheimer’s Program
There was nothing to be thankful about from Lilly’s disclosure that its potential Alzheimer’s therapy solanezumab failed to demonstrate significant improvement in cognition in a third large Phase III trial. But it does reinforce the wisdom of FDA’s standards for subgroup analysis in failed trials.
You may also be interested in...
Editorial cites Lilly's failed Alzheimer's candidate solanezumab to argue that looser efficacy standards could result in Medicare paying for ineffective drugs, but it's unlikely that a Scott Gottlieb-led FDA would have approved the drug.
Alzheimer drug’s development was discontinued after third disappointing Phase III trial, but given the kind of FDA commissioner candidates getting meetings with the President, maybe Lilly should reconsider.
As future of agency remains uncertain, report makes the case for strict approval standards.